Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Anders HM[original query] |
---|
Strategies, actions, and outcomes of pilot state programs in public health genomics, 2003-2008.
St Pierre J , Bach J , Duquette D , Oehlke K , Nystrom R , Silvey K , Zlot A , Giles R , Johnson J , Anders HM , Gwinn M , Bowen S , Khoury MJ . Prev Chronic Dis 2014 11 E97 State health departments in Michigan, Minnesota, Oregon, and Utah explored the use of genomic information, including family health history, in chronic disease prevention programs. To support these explorations, the Office of Public Health Genomics at the Centers for Disease Control and Prevention provided cooperative agreement funds from 2003 through 2008. The 4 states' chronic disease programs identified advocates, formed partnerships, and assessed public data; they integrated genomics into existing state plans for genetics and chronic disease prevention; they developed projects focused on prevention of asthma, cancer, cardiovascular disease, diabetes, and other chronic conditions; and they created educational curricula and materials for health workers, policymakers, and the public. Each state's program was different because of the need to adapt to existing culture, infrastructure, and resources, yet all were able to enhance their chronic disease prevention programs with the use of family health history, a low-tech "genomic tool." Additional states are drawing on the experience of these 4 states to develop their own approaches. |
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method.
Dotson WD , Douglas MP , Kolor K , Stewart AC , Bowen MS , Gwinn M , Wulf A , Anders HM , Chang CQ , Clyne M , Lam TK , Schully SD , Marrone M , Feero WG , Khoury MJ . Clin Pharmacol Ther 2013 95 (4) 394-402 As evidence accumulates on the use of genomic tests and other health-related applications of genomic technologies, decision makers may increasingly seek support in identifying which applications have sufficiently robust evidence to suggest they might be considered for action. As an interim working process to provide such support, we developed a horizon-scanning method that assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate an application of the method to pharmacogenomics tests. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure